Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022

This report describes data from two randomized, double-blind clinical trials that investigated COVID-19 rebound following treatment with or without nirmatrelvir/ritonavir.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Source Type: news